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The objective of this study was to evaluate the eﬀectiveness of traditional herbal medicines (Kampo) on the symptoms of Yusho.
Yusho is a mass food poisoning that was caused by ingestion of rice oil contaminated with dioxins and related organochlorines in
1968.PatientswithYushosuﬀerfromskinsymptoms(acneformeruptions,liabilitytosuppurationandpigmentation),respiratory
symptoms (cough and expectoration of sputum), neurological symptoms (numbness and paresthesia of extremities), arthralgia
and general fatigue, and no eﬀective treatment has yet been developed. In this clinical trial, four Kampo formulae (Bakumondo-
to, Keigai-rengyo-to, Gosha-jinki-gan and Hochu-ekki-to) were administered to four representative Yusho symptoms (respiratory,
skin, neurological symptoms and general fatigue), respectively. Twenty-seven Yusho patients were enrolled and two formulae were
administered to each patient for half-a-year each. The eﬀectiveness of Kampo formulae was estimated by changes in the intensity
of symptoms measured by a visual analogue scale (VAS) of 100 mm recorded at baseline and after administration of each formula.
The inﬂuence of Kampo formulae on patients’ quality of life (QOL) was also assessed by the SF-36 (NBS). Twenty-ﬁve patients
completed the treatment. Bakumondo-to signiﬁcantly improved respiratory symptoms as well as patients’ QOL in the context of
vitality, compared with other formulae. In contrast, Hochu-ekki-to impaired patients’ QOL in the context of physical functioning
and vitality, compared with other formulae. This study demonstrated for the ﬁrst time that a Kampo formula Bakumondo-to is
useful for treating respiratory symptoms caused by dioxins.
1.Introduction
A mass food poisoning involving at least 1900 individuals
occurred in western Japan in 1968, which was later referred
to as Yusho oil disease because it was caused by the ingestion
of rice bran oil contaminated with dioxins, polychlorinated
biphenyls (PCBs) and other related organochlorine com-
pounds [1–3]. Patients of Yusho presented various clinical
symptoms, such as acneform eruptions, comedos, dark-
brownish nail pigmentation, increased discharge from the
meibomian glands, pigmentation of oral mucosa, numbness
of extremities, cough with expectoration, articular swelling
and arthralgia, irregular menstruation in women, general
fatigue and stomachache [4]. Forty years have passed since
the outbreak, but patients still suﬀer from many symptoms
because no eﬀective therapy for Yusho has been developed.
Although blood levels of PCBs and dioxins in Yusho patients
have been gradually decreasing during the 40-year period,
recent studies showed that mean blood levels of total dioxins
and 2,3,4,7,8-pentachlorinated dibenzofuran (penta-CDF),
whichisrecognizedasthemostimportantcausativeagentfor
development of symptoms of Yusho, in Yusho patients from
2001 to 2003 were still 3.4–4.8 and 11.6–16.8 times higher,
respectively, than those in normal controls [5]. Blood levels
of dioxins in Yusho patients are known to be signiﬁcantly
correlated with the intensity of Yusho symptoms, such as2 Evidence-Based Complementary and Alternative Medicine
skin symptoms, general fatigue, respiratory symptoms and
neurological symptoms [6–8].
Kampo is a traditional herbal medicine that originated
in China, and has been developed into a unique form
in Japan. Each Kampo formula comprises several herbal
extracts intended to increase the treatment eﬀects and to
diminish the adverse reactions of each herb, and is selected
according to the pharmacological features and constitution
of each patient [9, 10]. In this clinical trial, four Kampo
formulae (Bakumondo-to, Keigai-rengyo-to, Hochu-ekki-
to and Gosha-jinki-gan) were selected for the following
four symptoms of Yusho, respectively: respiratory symptoms
(coughandexpectorationofsputum),skinsymptoms(acne-
form eruptions, liability to suppuration and pigmentation),
general fatigue and neurological symptoms (numbness and
paresthesia of extremities). Bakumondo-to is widely used
to treat chronic airway diseases such as bronchitis and
asthma because of its antitussive eﬀect [11, 12]. Keigai-
rengyo-to is indicated for the treatment of chronic purulent
diseases such as acne vulgaris because of its antibacterial
activities [13, 14]. Hochu-ekki-to has long been used for
the treatment of severe weakness in patients, especially those
with a delicate constitution, caused by general fatigue or
loss of appetite or ingestion [10]. Gosha-jinki-gan has been
widelyusedforthetreatmentofdiabeticneuropathy,urinary
frequency and incontinence, and lower limb/lumbar pain
[15]. The objective of this study was to determine the clinical
eﬀectiveness of these Kampo formulae for treatment of
the symptoms of Yusho. The inﬂuence of Kampo formulae
on patients’ quality of life (QOL), laboratory values of
blood, and blood concentrations of dioxins, PCBs and
polychlorinated quaterphenyl (PCQ) was also assessed.
2. Methods
2.1. Subjects. Patients aged ≥20 years who fulﬁlled the
diagnostic criteria for Yusho established by the National
Study Group for the Therapy of Yusho were eligible for this
study. Patients were not eligible for the study if they had
serious diseases (malignant neoplasms, hepatic disorders,
renal disorders or blood disorders), had been treated with
anyotherKampoformulaeformorethanfourweekspriorto
the study or were women with conﬁrmed or suspected preg-
nancy, nursing women or women who desired to become
pregnant during the trial. Patients who were judged to
have an ineligible health condition by medical doctors were
excluded.Thetrialprotocolwasapprovedbytheinstitutional
ethics committee of Kyushu University Hospital, and all
patients gave their written informed consents.
2.2. Preparation of Kampo Formulae. Each Kampo formula
was manufactured as a spray-dried powder of hot water
extracts obtained from several medicinal plants. The daily
d o s eo fe a c hf o r m u l aw a s7 . 5g ,e x c e p tB a k u m o n d o - t o( 9g ) ,
and was administered orally three times a day before each
meal.NinegramsofBakumondo-tocontained6gofextracts
from 10g enlarged part of the root of Ophiopogon japonicus
Ker-Gawler, 5g tuber of Pinellia ternata Breitenbach, 2g
root of Panax ginseng C.A. Meyer, 5g seed of Oryza sativa
Linne,3gfruitofZizyphusjujubaMillervar.intermisRehder,
and 2g root of Glycyrrhiza uralensis Fischer. Gosha-jinki-gan
(7.5g)contained4.5gofextractsfrom5grootofRehmannia
glutinosa Liboschitz var. purpurea Makino, 3g rhizome of
Dioscorea japonica Thunberg, 3g fruit of Cornus oﬃcinalis
Siebold et Zuccarini, 3g Sclerotium of Poria cocos Wolf,
3g rhizome of Alisma orientale Juzepczuk, 3g root bark
of Paeonia suﬀruticosa Andrews, 1g bark of the trunk of
CinnamomumcassiaBlume,1gtuberofAconitum japonicum
Thunberg, 3g root of Achyranthes fauriei Leveille et Vaniot,
and3gseedofPlantagoasiaticaLinne.Hochu-ekki-to(7.5g)
contained 5g of extracts from 4g root of Panax ginseng
C.A. Meyer, 4g root of Astragalus membranaceus Bunge,
4grhizomeofAtractylodes lancea De Candolle, 2g root of
Bupleurum falcatum Linne, 3g root of Angelica acutiloba
Kitagawa, 1g rhizome of Cimicifuga simplex Wormskjord,
2g pericarp of the ripe fruit of Citrus unshiu Markovich,
0.5g rhizome of Zingiber oﬃcinale Roscoe, 2g fruit of
Zizyphus jujuba Miller var. intermis Rehder, and 1.5g root
of Glycyrrhiza uralensis Fischer. 7.5g of Keigai-rengyo-to
contained 4.5g of extracts from 1.5g root of Scutellaria
baicalensis Georgi, 1.5g bark of Phellodendron amurense
Ruprecht,1.5grhizomeofCoptisjaponicaMakino,1.5groot
of Platycodon grandiﬂorus A. De Candolle, 1.5g immature
fruit of Citrus aurantium Linne var. daidai Makino, 1.5g
spike of Schizonepeta tenuifolia Briquet, 1.5g root of Bupleu-
rum falcatum Linne, 1.5g fruit of Gardenia jasminoides Ellis,
1.5g root of Rehmannia glutinosa Liboschitz var. purpurea
Makino, 1.5g root of Paeonia lactiﬂora Pallas, 1.5g rhizome
of Cnidium oﬃcinale Makino, 1.5g root of Angelica acutiloba
Kitagawa, 1.5g terrestrial part of Mentha arvensis Linne
var. piperascens Malinvaud, 1.5g root of Angelica dahurica
Bentham et Hooker, 1.5g root of Saposhnikovia divaricata
Schischkin, 1.5g fruit of Forsythia suspensa Vahl, and 1g root
of Glycyrrhiza uralensis Fischer. All four Kampo formulae
were generously supplied by Tsumura Co., Tokyo, Japan.
2.3. Endpoints. The primary endpoint was the intensity of
symptoms measured on a visual analogue scale (VAS) of
100mm. The target symptoms were general fatigue for
Hochu-ekki-to, skin symptoms (acneform eruptions, liabil-
ity to suppuration and pigmentation) for Keigai-rengyo-
to, neurological symptoms (numbness and paresthesia of
extremities) for Gosha-jinki-gan, and respiratory symptoms
(cough and expectoration of sputum) for Bakumondo-to.
Secondary endpoints were the intensity of other symptoms
for which each Kampo formula was not speciﬁcally targeted,
patients’ QOL evaluated by the SF-36 (NBS) [16], laboratory
values of blood, and blood concentrations of dioxins, PCBs
and PCQ.
Primary and secondary endpoints were measured at
baselineandaftereachtreatment.Laboratorytestswereaddi-
tionally conducted when possible side eﬀects were observed,
or optionally with any other reasons. The VAS and SF-36
were measured by trained nurses who had experience in
communicating with Yusho patients. A VAS was a horizontal
line, 100 mm in length, and the left-hand end (0 mm) repre-
sented no symptom, whereas the right-hand end (100mm)Evidence-Based Complementary and Alternative Medicine 3
represented the severest symptom. At baseline and after
eachtreatment,patientsreceivedaquestionnairehavingfour
lines of VAS for four symptoms. Trained nurses then asked
patientstomarkthepoint ontheline whichtheyrepresented
their current state of their symptoms. Nurses determined
the VAS score by measuring in millimeters from the left-
hand end to the point that patients had marked. Blood
samples were collected by the medical doctors and measured
by a contracted research company. Blood concentrations of
dioxins, PCBs and PCQ were measured by Fukuoka Institute
of Health and Environmental Sciences, Fukuoka, Japan. The
detailed method to measure the organochlorine compounds
is described by Todaka et al. [5].
2.4. Sample Size. Due to the limited number of Yusho
patients, two formulae were administered to each patient
for half-a-year each. Sample size could not be statistically
deﬁned, because no background information was available
on the VAS for the symptoms in Yusho patients. The
maximum number of eligible patients was estimated to be
100, considering the location of residence and the health
condition of patients. The prevalence of general fatigue, skin
symptoms, neurological symptoms and respiratory symp-
toms was estimated to be 60, 30, 50 and 60%, respectively,
by annual medical health check-ups from 2001 to 2003 for
Yusho patients [6].
2.5. Selection and Allocation of Formulae. When a candidate
was recruited, the minimum information suﬃcient for the
allocation was sent to one of the authors (S. Tokunaga). If
the patient complained of more than two symptoms, two
symptoms were selected according to severity of the symp-
toms, request of the patients and evenness of the number
of formulae to be allocated. The order of the symptoms for
which the Kampo formulae were prescribed was allocated by
the minimization method stratiﬁed by age (<70/≥70 years),
residency (Fukuoka, Nagasaki or Hiroshima prefecture) and
sex (male/female).
2.6. Statistical Methods. Analysis of the primary endpoint,
the eﬀectiveness of the Kampo formulae measured by the
changes in VAS from the baseline value, was evaluated
by the Student’s t-test. The eﬀectiveness of the formula
on the target symptom was compared with that of other
formulae on the same symptom. In the analyses of secondary
endpoints,ananalysisofvariance(ANOVA)withBonferroni
correction was performed on the eﬀectiveness of Kampo
formulae on symptoms other than the target symptom.
The inﬂuence of Kampo formulae on patients’ QOL
was evaluated by ANOVA with Bonferroni correction.
The concentrations of dioxins, PCBs and PCQ were
log-transformed because of highly discrete distribution
before applying ANOVA with Bonferroni correction. The
concentrations of 1,2,3,7,8-pentachlorodibenzo-p-dioxin
(penta-CDD), 1,2,3,4,7,8-hexa-CDD, 1,2,3,6,7,8-hexa-CDD,
1,2,3,7,8,9-hexa-CDD, 1,2,3,4,6,7,8-hepta-CDD, octa-CDD,
2,3,7,8-tetra-CDF, 2,3,4,7,8-penta-CDF, 1,2,3,4,7,8-hexa-
CDF,1,2,3,6,7,8-hexa-CDF,3,3 ,4,4 ,5-penta-CB(#126),and
3,3 ,4,4 ,5,5 -hexa-CB (#169) were statistically analyzed. The
concentrations of 2,3,7,8-tetra-CDD, 1,2,3,7,8-penta-CDF,
2,3,4,6,7,8-hexa-CDF, 1,2,3,7,8,9-hexa-CDF, 1,2,3,4,6,7,8-
hepta-CDF, 1,2,3,4,7,8,9-hepta-CDF, octa-CDF, 3,4,4 ,5-
tetra-CB (#81) and 3,3 ,4,4 -tetra-CB (#77), however, were
not analyzed because the concentrations of those congeners
in more than half of the patients were under the detection
limit. A two-tailed P<. 05 was considered statistically
signiﬁcant. All statistical tests were performed with Stata
10.1 (Stata Corp., College Station, TX, USA).
3. Results
3.1. Patient Enrollment. The ﬂowchart of patients through
the study is shown in Figure 1. Patients were ﬁrst recruited
at explanatory meetings conducted in three regions of
Fukuoka and Nagasaki prefectures. A questionnaire was
distributed at the meetings to inquire about participation
in the trial. Eighty-ﬁve patients answered the questionnaire.
After the meeting, an additional 11 patients inquired about
participation in the trial after getting information from
various sources, such as newspapers. Of the 96 patients who
inquired about the trial, 32 refused to participate and 14
were excluded due to their health condition. Another was a
potential Yusho patient who was not oﬃcially registered, and
two others moved and were unable to be contacted. Of the
remaining 47 patients to whom two formulae were allocated,
20 could not enter the trial because of illness found after
a detailed health check, the diﬃculty of receiving regular
health check ups and refusal to participate. The remaining
27 patients participated in the trial.
Registration of patients followed by the ﬁrst treatment
occurred from October 26, 2005 to October 12, 2006.
Duringtheﬁrsttreatment,thenumberofpatientsprescribed
with Hochu-ekki-to, Keigai-rengyo-to, Gosha-jinki-gan and
Bakumondo-to, was 5, 8, 8 and 6, respectively. One patient
prescribed with Hochu-ekki-to and one with Gosha-jinki-
gan withdrew from the trial after the ﬁrst administration.
The second treatment started on April 12, 2006
and ended on March 29, 2007. During the second
treatment, Hochu-ekki-to, Kaigai-rengyo-to, Gosha-jinki-
gan and Bakumondo-to were administered to 9, 5, 5
and 6 patients, respectively. The second treatment ended
between September 28, 2006 and October 18, 2007. In
total, Hochu-ekki-to, Kaigai-rengyo-to, Gosha-jinki-gan and
Bakumondo-to were administered to 14, 13, 13 and 12
patients, respectively. Details of the combination of formulae
administered to each patient were shown in Table 1.
3.2. Background of the Participants. Of the 27 patients aged
51–86 years (mean = 69.4, standard deviation (SD) = 7.9)
who participated in this trial, 16 were men (59.3%) and
11 were women (40.7%). They were from Fukuoka (10
patients), Nagasaki (8 patients) and Hiroshima (9 patients)
prefectures. The geometric mean blood concentrations (pg/g
lipid) (5 to 95 percentiles) of dioxins and PCBs were
11.8 (9.3, 16.3) for 1,2,3,7,8-penta-CDD, 2.8 (2.3, 3.7)
for 1,2,3,4,7,8-hexa-CDD, 46.0 (31.1, 76.8) for 1,2,3,6,7,8-
hexa-CDD, 3.6 (2.9, 5.5) for 1,2,3,7,8,9-hexa-CDD, 43.34 Evidence-Based Complementary and Alternative Medicine
Table 1: Combination of Kampo formulae administered to each patient.
Second formula
Hochu-ekki-to Keigai-rengyo-to Gosha-jinki-gan Bakumondo-to (Withdrew) Total
First formula
Hochu-ekki-to — 1 3 0 1 5
Keigai-rengyo-to 4 — 1 3 0 8
Gosha-jinki-gan 4 0 — 3 1 8
Bakumondo-to 1 4 1 — 0 6
Total 9 5 5 6 2 27
Participation applicants
(oﬃcially registered Yusho patients)
n = 96
Refused
n = 32
Excluded due to health condition
n = 14
Moved or
not oﬃcially registered patients
n = 3
Refused or
excluded due to health condition
n = 20
Withdrew
n = 2
Administered 2nd formula
n = 25
Administered 1st formula
n = 27
Allocated
n = 47
Figure 1: Flow of patient through the study.
(29.6,54.5)for1,2,3,4,6,7,8-hepta-CDD,702.2(456.8,987.9)
for octa-CDD, 1.7 (1.3, 3.1) for 2,3,7,8-tetra-CDF, 132.9
(78.5, 385.1) for 2,3,4,7,8-penta-CDF, 29.5 (15.2, 54.2) for
1,2,3,4,7,8-hexa-CDF, 15.3 (8.1, 20.8) for 1,2,3,6,7,8-hexa-
CDF, 101.4 (68.2, 172.8) for 3,3 ,4,4 ,5-penta-CB (#126) and
198.9 (160.7, 261.5) for 3,3 ,4,4 ,5,5 -hexa-CB (#169). The
geometric mean (5 to 95 percentile) blood concentration for
PCQ was 0.6 (0.0, 4.4)ng/g.
3.3. Eﬀectiveness on Clinical Symptoms. Changes in the
intensity of symptoms measured by VAS from baseline
to the end of administration of formulae in each patient
were presented in Figure 2. Figure 3 shows the diﬀerences
in eﬀectiveness measured by VAS between the Kampo
formulae prescribed to the target symptom and the formulae
primarily prescribed to other symptoms. The diﬀerences
in eﬀectiveness on general fatigue, skin and neurological
symptoms between Kampo formula primarily prescribed to
those symptoms and other formulae were not statistically
signiﬁcant. Bakumondo-to, which was administered to 11
patients, alleviated respiratory symptoms, as demonstrated
by a mean change of −12.2 (SD = 17.6) on the intensity
of symptoms. On the other hand, respiratory symptoms
of patients administered other Kampo formulae had a
decreased VAS mean change of −1.9 (SD = 13.2). This
diﬀerence in eﬀectiveness was 10.3 (95% conﬁdence interval:
0.5–20.0) and was statistically signiﬁcant (P = .04). The
changes in VAS after administration of the Kampo formulae
for symptoms other than the target symptom are compared
with each other as secondary endpoints in Figure 4.T h e
eﬀectiveness of the formulae was not statistically signiﬁcant,
except for Keigai-rengyo-to, which worsened general fatigue
by a marginal signiﬁcance (P = .07).
3.4. Inﬂuence on QOL. The baseline scores on the SF-36
(mean (SD)) were 36.9 (14.3) for physical functioning, 34.9
(10.8) for role physical, 38.0 (10.2) for bodily pain, 38.3
(9.8) for general health, 41.8 (9.5) for vitality, 39.3 (10.4)
for social functioning, 35.5 (12.5) for role emotional, and
42.4 (9.3) for mental health. The comparison of changes in
patients’ QOL from baseline after administration of Kampo
formulae is shown in Figure 5. Physical functioning and
vitality scores on the SF-36 decreased after administration
of Hochu-ekki-to compared to changes in SF-36 scores after
administration of other formulae (P = .05 and .03, resp.).
AftertreatmentwithBakumondo-to,thevitalityscoreonthe
SF-36 increased compared to the scores after administration
of other formulae (P = .04). These results indicated that
Bakumondo-to improved patients’ QOL in the context of
vitality, whereas Hochu-ekki-to impaired patients’ QOL in
the context of physical functioning and vitality, compared
with other formulae.
3.5. Inﬂuence on Blood Dioxins, PCBs, PCQ and Laboratory
Values of Blood. The comparison of changes in blood
concentrations of dioxins, PCBs and PCQ did not show
any statistically signiﬁcant diﬀerences between the Kampo
formulae, except for 1,2,3,6,7,8-hexa-CDF, which was not a
causative toxic compound for Yusho (data not shown). The
concentration of 1,2,3,6,7,8-hexa-CDF decreased by 22%
compared to other formulae (P = .01) after administration
of Gosha-jinki-gan. The mean (min–max) number of labo-
ratory tests for each patient was 6.7 [2–9, 11–13]. Less thanEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Changes in the intensity of symptoms by Kampo formulae in each patient. The intensity of symptoms was measured by VAS at
the baseline and after treatment of 6 months. The values of the same patient were connected by the solid line if the symptom was targeted by
the formula, or by the dashed line otherwise.
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∗
Figure 3: The eﬀectiveness of Kampo formulae on the target
symptom;theprimaryendpoint.Thetargetsymptomsweregeneral
fatigue for Hochu-ekki-to, skin symptoms for Keigai-rengyo-
to, neurological symptoms for Gosha-jinki-gan and respiratory
symptoms for Bakumondo-to. The eﬀectiveness of the Kampo
formulae was evaluated by changes in intensity of the symptoms
from baseline to the end of administration, which was measured
by VAS. Diﬀerences in eﬀectiveness between the formulae admin-
istered for the target symptom and other formulae for the same
symptom are shown. Data are means (dots) and 95% conﬁdence
intervals (bars). Bakumondo-to signiﬁcantly improved respiratory
symptoms compared with other formulae. ∗P<. 05 by Student’s
t-test.
20% of observed values were outside the range of ± 15% of
the standard range of each hematological component, except
for triglycerides and blood sugar (data not shown).
4. Discussion
In the present study, Bakumondo-to signiﬁcantly improved
respiratory symptoms (cough and expectoration of sputum)
of Yusho compared with other formulae. Bakumondo-to
also improved patients’ QOL in the context of vitality.
On the other hand, Keigai-rengyo-to did not improve
skin symptoms of Yusho, but marginally worsened general
fatigue compared with other formulae. Hochu-ekki-to did
not reduce general fatigue in Yusho patients, but impaired
patients’ QOL in the context of physical functioning and
vitality compared with other formulae, suggesting that it
may not be appropriate to prescribe Keigai-rengyo-to and
Hochu-ekki-to for Yusho patients. Gosha-jinki-gan did not
demonstrateanyinﬂuenceonthesymptomsofYusho.Inthis
study, patients were administered two Kampo formulae for
half-a-year each. Although we did not observe any unusual
eﬀects by any combination of formulae, and Bakumondo-
to constantly improved respiratory symptoms irrespective
of combinations, contaminations of other formulae to
the eﬀectiveness on the target symptom would not be
excluded completely, because statistical analyses were not
available due to very limited number of patients in each
combination. Additionally, none of the Kampo formulae
produced serious adverse eﬀects, and blood concentrations
of dioxins and related compounds were little aﬀected by
the Kampo formulae. Although 40 years have passed since
the outbreak of Yusho, and most patients still suﬀer from
v a r i o u ss y m p t o m s[ 6], no eﬀective treatment for Yusho has
been developed. Because blood concentrations of dioxins in
Yusho patients signiﬁcantly correlated with the intensity of
Yusho symptoms [6–8], medicines that accelerate excretion6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: The eﬀectiveness of Kampo formulae on symptoms other than the target; the secondary endpoints. The eﬀectiveness of the
Kampo formulae was evaluated by changes in intensity of the symptoms from baseline to the end of administration, which measured by
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and 95% conﬁdence intervals (bars). The eﬀectiveness of the formulae was not statistically signiﬁcant, except for Keigai-rengyo-to, which
worsened general fatigue by a marginal signiﬁcance (P = .07 by ANOVA with Bonferroni correction).
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Figure 5:ChangesinSF-36frombaselinevaluesafteradministrationofKampoformulae.TheinﬂuenceoftheKampoformulaeonpatients’
QOL was evaluated by changes in SF-36 from baseline to the end of administration. Diﬀerences in inﬂuence on the scores of SF-36 between
the formulae are shown. Data are means (dots) and 95% conﬁdence intervals (bars). Bakumondo-to signiﬁcantly improved patients’ QOL
in the context of vitality, whereas Hochu-ekki-to signiﬁcantly impaired patients’ QOL in the context of physical functioning and vitality,
compared with other formulae. ∗P<. 05 by ANOVA with Bonferroni correction.Evidence-Based Complementary and Alternative Medicine 7
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Figure 6: Hypothetical diagrams of the eﬀect of Bakumondo-to. (a) After ligation of dioxins to the AhR, the receptor translocates from the
cytosol to the nucleus, binds to DRE, and activates transcription of CYP1A1, mucin and other genes in bronchiolar Clara cells. Excess mucin
production from Clara cells by dioxins is supposed to be responsible at least in part for respiratory symptoms of Yusho patients. (b) Active
ingredients in Bakumondo-to would block activation of the AhR by competitive interference with the interaction between dioxins and the
AhR, and inhibit transcription of mucin in Clara cells, leading to improvement of respiratory symptoms of Yusho patients.
of dioxins or convert dioxins to harmless metabolites could
provide a permanent cure for Yusho. Yoshimura et al. [17]
extensively investigated methods to accelerate the excretion
of such organochlorine compounds in an animal model.
They demonstrated that in rats the oral administration
of diﬀerent antidotes (squalene, paraﬃn, cholestyramine
and charcoal) increased the excretion of 2,3,4,7,8-penta-
CDF 2–5 times more than amounts excreted in the control
group [17, 18]. In addition to these antidotes, it was found
that dietary ﬁber accelerated the excretion of congeners
of polychlorinated biphenyls [19]. Based on these studies,
cholestyramine and rice bran ﬁber were administered for 2
weekstoasmallnumberofpatientswithYushoandYucheng,
another poisoning caused by ingestion of oil contaminated
with dioxins. The amounts of 2,3,4,7,8-penta-CDF in their
feces actually increased, although beneﬁcial clinical eﬀects
were not apparent, possibly due to the short trial period
[20].8 Evidence-Based Complementary and Alternative Medicine
Another alternative treatment for Yusho would be antag-
onistic compounds against the aryl hydrocarbon receptor
(AhR), which is well known as a receptor for dioxins and
other polycyclic aromatic hydrocarbons [21]. The AhR is
a ligand-activated transcription factor that is ubiquitously
distributed in the body, and after ligation of dioxins to
the AhR, the receptor translocates from the cytosol to the
nucleus, heterodimerizes with the AhR nuclear translocator
(ARNT), and binds to an enhancer sequence, called a
dioxin response element (DRE), of several drug metabo-
lizing enzymes, such as cytochrome P450 1A1 (CYP1A1)
[21]. Previous investigations using AhR-null mutant mice
conﬁrmed a critical role of the AhR in the toxic eﬀects of
dioxins [22, 23]. The present functional role of the AhR
was derived mainly from recent studies using environmental
contaminants such as dioxins. Therefore, the AhR might
primarily be a regulatory receptor for exogenous natural
productssuchasfoodconstituents.Variouspolyphenolcom-
pounds that are present in vegetables, fruits and herbs have
been shown to have antagonistic potencies against the AhR.
Flavones (apigenin, luteolin, baicalein), ﬂavonols (quercetin,
kaempferol, myricetin), ﬂavanones (naringenin, hesperetin),
anthraquinones (emodin, alizarin), curcumin, resveratrol
andcoumestrolhavestronginhibitorypotenciesagainstAhR
activationinducedby2,3,7,8-tetra-CDD[24–27].Flavonoids
belonging to the ﬂavone, ﬂavonol and ﬂavonone subclasses
directlybindtotheAhRcomplexinthecytosol,andsuppress
AhR transformation by competitive inhibition of binding
between the AhR and its agonist [28]. In this study, the
eﬀectiveness of the Kampo formula on the target symptom
was compared with that of other formulae on the same
symptom. We hypothesized that the formulae might have
not only expected eﬀects for target symptoms but also
antagonistic activities on dioxins by unknown ingredients.
Wesupposedthatwewouldﬁndformulaehavinganti-dioxin
activities by comparing the eﬀectiveness of the formula
to the target symptom with other formulae on the same
symptom.
The intensity of respiratory symptoms, such as cough
and expectoration of sputum, were shown to be signiﬁ-
cantly correlated with blood concentrations of dioxins in
Yusho patients [7]. In addition, bronchiolar Clara cells and
ciliated cells constitutively express the AhR, and dioxins
such as 2,3,7,8-tetra-CDD and poly-CDFs impaired Clara
cells in the lung of rats [29, 30]. Recently, 2,3,7,8-tetra-
CDD was shown to induce mucin production from a
Clara cell-derived cell line [31]. Therefore, activation of
the AhR by dioxins could cause the respiratory symptoms
in Yusho patients. Although further studies would be
needed to clarify how Bakumondo-to improves respiratory
symptoms of Yusho, active ingredients in Bakumondo-to
might interfere with the interaction between dioxins and
the AhR in bronchioles, and improve respiratory symptoms
in Yusho patients. Although we have not identiﬁed what
constituents in Bakumondo-to are eﬀective yet, a hypothet-
ical diagram is shown in Figure 6.W ea r en o wc o n d u c t -
ing basic studies to investigate the mechanism by which
Bakumondo-to and its constituents aﬀect the function of the
AhR.
In conclusion, we have demonstrated for the ﬁrst
time that a Kampo formula, Bakumondo-to, signiﬁcantly
improved respiratory symptoms (cough and expectoration
of sputum) of Yusho compared with other formulae. This
formula may be eﬀective for the treatment of respiratory
symptoms of patients intoxicated with other dioxins, such as
2,3,7,8-tetra-CDD.
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